Monday, March 25, 2019—In a phase 2 clinical trial (NCT03765762), the first participant has received a dose of the proprietary plasma fraction (PPF)(GRF6019) developed by Alkahest (San Carlos, CA) i…
Logan Schneider, MD
March/April 2019—Sleep has a critical role in brain health and is an essential part of improving neurologic care for all of our patients.
Raman K. Malhotra, MD
March/April 2019—Sleep problems are common and treatable in neurodegenerative disorders, and may also be a treatable risk factor and early biomarker.
Fiona Barwick, PhD
March/April 2019—Sleep disturbances are symptoms of psychiatric conditions that can worsen prognosis; however, nonpharmacologic treatments are available and effective.
With Mathias Basner, MD, PhD, MSc
March/April 2019—A daily adequate dose of healthy sleep is the most effective performance enhancement on the planet.
Friday, March 08, 2019—A phase 3 study to investigate a humanized monoclonal antibody as a potential therapy for mild cognitive impairment from Alzheimer’s disease (AD)began this month. T…
Friday, March 01, 2019—Analysis of genetic data from more than 94,000 people has revealed new risk genes for Alzheimer’s disease (AD) and confirmed 20 known others. Researchers also reported t…
Wednesday, February 13, 2019—HealthPartners Neuroscience Center (St. Paul, MN) has announced they will be conducting the first study of the Muscle2Mind exercise program for patients with Alzheimer’s…
